These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 36198428)

  • 21. Characterization of Pediatric Reports in the US Food and Drug Administration Adverse Event Reporting System from 2010-2020: A Cross-Sectional Study.
    Phan M; Cheng C; Dang V; Wu E; Muñoz MA
    Ther Innov Regul Sci; 2023 Sep; 57(5):1062-1073. PubMed ID: 37351842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An Algorithm to Identify Generic Drugs in the FDA Adverse Event Reporting System.
    Iyer G; Marimuthu SP; Segal JB; Singh S
    Drug Saf; 2017 Sep; 40(9):799-808. PubMed ID: 28593504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of the impact of scheduled postmarketing safety summary analyses on regulatory actions.
    Sekine S; Pinnow EE; Wu E; Kurtzig R; Hall M; Dal Pan GJ
    Clin Pharmacol Ther; 2016 Jul; 100(1):102-8. PubMed ID: 26853718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
    Peng L; Xiao K; Ottaviani S; Stebbing J; Wang YJ
    Expert Opin Drug Saf; 2020 Nov; 19(11):1505-1511. PubMed ID: 32693646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Patel NM; Stottlemyer BA; Gray MP; Boyce RD; Kane-Gill SL
    Cardiovasc Drugs Ther; 2022 Apr; 36(2):309-322. PubMed ID: 33599896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).
    Alatawi YM; Hansen RA
    Expert Opin Drug Saf; 2017 Jul; 16(7):761-767. PubMed ID: 28447485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of a New Consumer Form on the Quantity and Quality of Adverse Event Reports Submitted to the United States Food and Drug Administration.
    Muñoz MA; Delcher C; Dal Pan GJ; Kortepeter CM; Wu E; Wei YJ; Xiao H; Winterstein AG
    Pharmacotherapy; 2019 Nov; 39(11):1042-1052. PubMed ID: 31479525
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sources of Evidence Triggering and Supporting Safety-Related Labeling Changes: A 10-Year Longitudinal Assessment of 22 New Molecular Entities Approved in 2008 by the US Food and Drug Administration.
    Croteau D; Pinnow E; Wu E; Muñoz M; Bulatao I; Dal Pan G
    Drug Saf; 2022 Feb; 45(2):169-180. PubMed ID: 35113347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM
    Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pediatric Drug Safety Surveillance in FDA-AERS: A Description of Adverse Events from GRiP Project.
    de Bie S; Ferrajolo C; Straus SM; Verhamme KM; Bonhoeffer J; Wong IC; Sturkenboom MC;
    PLoS One; 2015; 10(6):e0130399. PubMed ID: 26090678
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging Causes of Drug-Induced Anaphylaxis: A Review of Anaphylaxis-Associated Reports in the FDA Adverse Event Reporting System (FAERS).
    Yu RJ; Krantz MS; Phillips EJ; Stone CA
    J Allergy Clin Immunol Pract; 2021 Feb; 9(2):819-829.e2. PubMed ID: 32992044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug Repurposing Using FDA Adverse Event Reporting System (FAERS) Database.
    Morris R; Ali R; Cheng F
    Curr Drug Targets; 2024; 25(7):454-464. PubMed ID: 38566381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety signals of albumin-bound paclitaxel: Data mining of the Food and Drug Administration adverse event reporting system.
    Wang Y; Liu X
    Indian J Pharmacol; 2023; 55(3):167-173. PubMed ID: 37555411
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utilizing Deep Learning for Detecting Adverse Drug Events in Structured and Unstructured Regulatory Drug Data Sets.
    Knisely BM; Hatim Q; Vaughn-Cooke M
    Pharmaceut Med; 2022 Oct; 36(5):307-317. PubMed ID: 35871475
    [TBL] [Abstract][Full Text] [Related]  

  • 37. US Food and Drug Administration regulatory reviewer disagreements and postmarket safety actions among new therapeutics.
    Eadie A; MacGregor A; Wallach J; Ross J; Herder M
    BMJ Evid Based Med; 2023 Jun; 28(3):151-156. PubMed ID: 36944478
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Methodological Considerations for Comparison of Brand Versus Generic Versus Authorized Generic Adverse Event Reports in the US Food and Drug Administration Adverse Event Reporting System (FAERS).
    Rahman MM; Alatawi Y; Cheng N; Qian J; Peissig PL; Berg RL; Page DC; Hansen RA
    Clin Drug Investig; 2017 Dec; 37(12):1143-1152. PubMed ID: 28933038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS).
    Omar NE; Fahmy Soliman AI; Eshra M; Saeed T; Hamad A; Abou-Ali A
    ESMO Open; 2021 Dec; 6(6):100315. PubMed ID: 34864500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Lawyer-Submitted Reports on Signals of Disproportional Reporting in the Food and Drug Administration's Adverse Event Reporting System.
    Rogers JR; Sarpatwari A; Desai RJ; Bohn JM; Khan NF; Kesselheim AS; Fischer MA; Gagne JJ; Connolly JG
    Drug Saf; 2019 Jan; 42(1):85-93. PubMed ID: 30066315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.